AERI [NASD]
Aerie Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.47 Insider Own1.50% Shs Outstand47.52M Perf Week-19.10%
Market Cap302.31M Forward P/E- EPS next Y-1.30 Insider Trans0.00% Shs Float40.63M Perf Month-25.69%
Income-68.70M PEG- EPS next Q-0.58 Inst Own- Short Float13.85% Perf Quarter5.14%
Sales201.00M P/S1.50 EPS this Y59.50% Inst Trans1.46% Short Ratio7.41 Perf Half Y-38.87%
Book/sh-2.65 P/B- EPS next Y39.90% ROA-17.90% Target Price18.67 Perf Year-64.15%
Cash/sh3.83 P/C1.55 EPS next 5Y- ROE107.60% 52W Range5.46 - 19.26 Perf YTD-15.53%
Dividend- P/FCF- EPS past 5Y13.80% ROI-21.60% 52W High-69.21% Beta0.70
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin86.60% 52W Low8.61% ATR0.59
Employees376 Current Ratio2.70 Sales Q/Q29.60% Oper. Margin-22.80% RSI (14)37.44 Volatility9.77% 9.02%
OptionableYes Debt/Eq- EPS Q/Q17.00% Profit Margin-34.20% Rel Volume1.05 Prev Close6.47
ShortableYes LT Debt/Eq- EarningsMay 05 AMC Payout- Avg Volume759.48K Price5.93
Recom2.00 SMA20-14.95% SMA50-25.55% SMA200-39.22% Volume800,304 Change-8.35%
Oct-19-20Downgrade BofA Securities Neutral → Underperform $14 → $9
Sep-08-20Resumed Guggenheim Buy $20
Aug-07-20Reiterated Needham Buy $32 → $26
Jun-01-20Resumed Oppenheimer Outperform $22 → $24
May-07-20Reiterated H.C. Wainwright Buy $37 → $31
Jan-10-20Initiated BofA/Merrill Neutral $27
Jan-09-20Initiated SunTrust Buy $32
Dec-19-19Initiated Citigroup Buy $36
Nov-07-19Reiterated H.C. Wainwright Buy $55 → $41
Oct-30-19Reiterated Needham Buy $54 → $48
Aug-08-19Reiterated Needham Buy $74 → $54
Aug-08-19Reiterated Cantor Fitzgerald Overweight $85 → $62
Mar-21-19Initiated Piper Jaffray Overweight $80
Jul-13-18Reiterated Needham Buy $76 → $86
Feb-16-18Resumed H.C. Wainwright Buy $78
Jan-26-18Initiated Seaport Global Securities Buy $78
Oct-24-17Initiated Guggenheim Buy $80
Oct-16-17Reiterated Needham Buy $65 → $76
Jul-20-17Reiterated Cantor Fitzgerald Overweight $56 → $62
May-25-17Reiterated Needham Buy $58 → $65
May-24-22 07:30AM  
May-07-22 09:28AM  
May-06-22 03:48PM  
May-05-22 05:55PM  
04:01PM  
Apr-28-22 04:35PM  
Apr-26-22 04:05PM  
Apr-20-22 04:05PM  
Apr-11-22 02:54PM  
Apr-06-22 04:30PM  
Mar-18-22 07:00AM  
Mar-17-22 10:45AM  
Feb-25-22 10:14AM  
Feb-24-22 06:00PM  
04:01PM  
06:30AM  
Feb-23-22 11:44AM  
Feb-17-22 04:45PM  
03:03PM  
Feb-03-22 04:42AM  
Jan-27-22 10:50AM  
Jan-26-22 07:31PM  
Dec-22-21 04:01PM  
12:13PM  
Dec-16-21 06:30AM  
Dec-09-21 02:15PM  
Dec-07-21 02:00AM  
Nov-09-21 04:30PM  
Nov-05-21 01:31PM  
10:37AM  
06:33AM  
Nov-04-21 05:15PM  
04:01PM  
Oct-28-21 03:06PM  
07:30AM  
Oct-27-21 09:36AM  
Oct-21-21 04:01PM  
Oct-12-21 06:30AM  
Oct-07-21 04:01PM  
Oct-06-21 07:30AM  
Sep-27-21 07:30AM  
Sep-22-21 12:16PM  
Sep-20-21 06:30AM  
Sep-17-21 07:40AM  
05:28AM  
Sep-16-21 04:13PM  
02:46PM  
11:19AM  
10:20AM  
05:59AM  
Sep-15-21 04:01PM  
Sep-13-21 06:30AM  
Sep-07-21 07:30AM  
06:30AM  
Sep-03-21 11:31AM  
Aug-12-21 07:30AM  
Aug-05-21 11:42AM  
Aug-04-21 11:31PM  
05:15PM  
04:01PM  
Jul-28-21 07:30AM  
Jul-20-21 04:01PM  
12:01AM  
Jul-15-21 06:30AM  
Jun-21-21 07:00AM  
06:45AM  
Jun-17-21 06:30AM  
Jun-15-21 07:30AM  
Jun-04-21 11:31AM  
May-26-21 06:34PM  
May-06-21 01:24PM  
07:30AM  
May-05-21 06:05PM  
04:01PM  
03:15PM  
May-04-21 09:17AM  
08:46AM  
Apr-29-21 06:30AM  
Apr-28-21 12:34PM  
07:30AM  
06:30AM  
Apr-19-21 06:30AM  
Apr-07-21 07:30AM  
Mar-30-21 08:05AM  
Mar-27-21 11:31AM  
Mar-11-21 07:30AM  
Mar-03-21 05:33PM  
Mar-01-21 10:59AM  
10:30AM  
Feb-28-21 04:59AM  
Feb-25-21 05:45PM  
04:01PM  
03:15PM  
Feb-22-21 07:30AM  
Feb-18-21 07:30AM  
Jan-11-21 06:30AM  
Dec-16-20 11:07PM  
Dec-05-20 11:31AM  
Dec-03-20 11:17PM  
Nov-25-20 10:36AM  
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.